Literature DB >> 10867966

Effects of methyllycaconitine (MLA), an alpha 7 nicotinic receptor antagonist, on nicotine- and cocaine-induced potentiation of brain stimulation reward.

G Panagis1, A Kastellakis, C Spyraki, G Nomikos.   

Abstract

It has been shown that nicotine facilitates intracranial self-stimulation (ICSS) reward and that nicotinic acetylcholine receptors (nAChRs) in the ventral tegmental area (VTA) are of primary importance for its reinforcing and dependence-producing actions. Recently, we have shown that alpha 7 nicotinic receptors in the VTA contribute to both the acute effects of nicotine on the mesolimbic dopamine system, as well as to nicotine withdrawal reactions. However, it is not yet known whether the same receptor conformation is directly involved in the reinforcing actions of nicotine. Here, using the curve-shift method we studied the effects of methyllycaconitine (MLA), a selective alpha 7 receptor antagonist, microinjected (graded doses: 1, 3, 9 micrograms/microliter per side) into the VTA on the rewarding efficacy of lateral hypothalamic self-stimulation and on the systemic nicotine-induced potentiation of brain stimulation reward. MLA did not affect baseline self-stimulation. Nicotine produced a significant reduction in ICSS threshold, without altering maximal rates of responding, while MLA attenuated the effect of nicotine at the two lower doses. Given the reported interaction between nicotine and cocaine at both the neuronal and the behavioral level, we also examined whether alpha 7 receptor antagonism within the VTA can affect the reinforcing action of cocaine, as measured with ICSS. Interestingly, MLA attenuated the reinforcing effect of cocaine in all doses tested, without altering the maximal rate of responding, i.e. the performance of the animals. These results suggest that alpha 7 nAChRs in the VTA are involved in mediating the reinforcing actions of drugs of abuse, such as nicotine and cocaine, and provide evidence that alpha 7 nAChR antagonists may be clinically useful in attenuating the rewarding effects of addictive drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10867966     DOI: 10.1007/s002130000384

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

1.  The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.

Authors:  Arlene C Pak; Charles R Ashby; Christian A Heidbreder; Maria Pilla; Jeremy Gilbert; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Int J Neuropsychopharmacol       Date:  2006-08-31       Impact factor: 5.176

2.  Diminished nicotine withdrawal in adolescent rats: implications for vulnerability to addiction.

Authors:  Laura E O'Dell; Adie W Bruijnzeel; Ron T Smith; Loren H Parsons; Michele L Merves; Bruce A Goldberger; Heather N Richardson; George F Koob; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2006-04-06       Impact factor: 4.530

3.  TC-2559 excites dopaminergic neurones in the ventral tegmental area by stimulating alpha4beta2-like nicotinic acetylcholine receptors in anaesthetised rats.

Authors:  Yun Wang; John L Sherwood; Colin P Miles; Gary Whiffin; David Lodge
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 4.  The neurocircuitry of addiction: an overview.

Authors:  M W Feltenstein; R E See
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

5.  Dopamine D₂ and acetylcholine α7 nicotinic receptors have subcellular distributions favoring mediation of convergent signaling in the mouse ventral tegmental area.

Authors:  M Garzón; A M Duffy; J Chan; M-K Lynch; K Mackie; V M Pickel
Journal:  Neuroscience       Date:  2013-08-15       Impact factor: 3.590

Review 6.  Future pharmacological treatments for substance use disorders.

Authors:  Ariadna Forray; Mehmet Sofuoglu
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

7.  Tolerance to nicotine in mice lacking alpha7 nicotinic receptors.

Authors:  C Naylor; D Quarta; C Fernandes; I P Stolerman
Journal:  Psychopharmacology (Berl)       Date:  2005-02-19       Impact factor: 4.530

Review 8.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

Review 9.  Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.

Authors:  Christie D Fowler; Michael A Arends; Paul J Kenny
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

10.  Intermittent nicotine exposure upregulates nAChRs in VTA dopamine neurons and sensitises locomotor responding to the drug.

Authors:  Lorinda K Baker; Danyan Mao; Henry Chi; Anitha P Govind; Yolanda F Vallejo; Michael Iacoviello; Stacy Herrera; James J Cortright; William N Green; Daniel S McGehee; Paul Vezina
Journal:  Eur J Neurosci       Date:  2013-01-21       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.